Abstract
Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Current Enzyme Inhibition
Title: Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Volume: 6 Issue: 2
Author(s): Hai-Chun Yang, Yiqin Zuo and Agnes B. Fogo
Affiliation:
Keywords: TGF-β, kidney, fibrosis
Abstract: Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.
Export Options
About this article
Cite this article as:
Yang Hai-Chun, Zuo Yiqin and B. Fogo Agnes, Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791233042
DOI https://dx.doi.org/10.2174/157340810791233042 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optimized High-Yield Purification of Obesity-Associated Melanocortin 4 Receptor
Protein & Peptide Letters Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients
Current Vascular Pharmacology Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Adherence to Cardiac Practice Guidelines in the Management of Non-ST-Elevation Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Current Pharmaceutical Design Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Biomarkers of Subclinical Atherosclerosis and Natural Products as Complementary Alternative Medicine
Current Pharmaceutical Design EDITORIAL: “The Faces of Mania: The Legacy of Athanasios Koukopoulos”
Current Neuropharmacology Subject Index to Volume 2
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Introduction from the Guest Editor: The Many Facets of Heme Oxygenase
Current Neurovascular Research Medicinal Chemistry Meets Proteomics: Fractionation of the Human Plasma Proteome
Current Medicinal Chemistry Editorial [Hot Topic: Nitric Oxide and Hydrogen Sulfide - Contribution of Gaseous Messengers to the Cardiovascular Control (Guest Editor: Sona Cacanyiova)]
Current Pharmaceutical Biotechnology Protease Inhibitors in the Clinic
Medicinal Chemistry Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Plasma Renalase in Chronic Kidney Disease: Differences and Similarities between Humans and Rats
Current Hypertension Reviews Teenage-Pregnancies - A Biomedical and a Sociocultural Approach to a Current Problem
Current Women`s Health Reviews Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters